He Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
He Huang has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
Hong-Yao Xu
Nanjing Hospital Affiliated to Nanjing Medical University, Nanjing First Hospital, Nanjing 210006, Jiangsu, China
1 shared publication- Hongyao Xu
Department of Sports Medicine and Joint Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, China
1 shared publication - Jianying Zhang
MechanoBiology Laboratory, Bethel Musculoskeletal Research Center, Department of Orthopaedic Surgery University of Pittsburgh School of Medicine Pittsburgh Pennsylvania USA
1 shared publication Zhi-Hong Dai
Nanjing Hospital Affiliated to Nanjing Medical University, Nanjing First Hospital, Nanjing 210006, Jiangsu, China
1 shared publication
Latest Publications
- Open Access
- 5 June 2019
- Published by IntechOpen
Current Tissue Engineering Approaches for Cartilage Regeneration
Cartilage is one of the critical tissues existed in human and animal bodies. Unlike most tissues, cartilage does not have blood vessels, nerves, and lymphatics. Most cartilage tissues in vivo are subjected to large mechanical loads, and its principal function is to provide a smooth and lubricated surface to facilitate the transmission of mechanical loads with a low frictional coefficient. As a result, cartilage tissues are easily injured. Cartilage defects are frequently caused by trauma, aging, congenital diseases (osteochondritis), and many more factors such as endocrine pathologies and cancer. The damaged cartilage has a limited capacity for healing and repairing. Thus, restoration of normal structure and function to damaged cartilage is one of the most challenging areas in orthopedic research and sports medicine. Tissue engineering provides a prospective alternative strategy by seeding chondrogenic cells into or onto biocompatible scaffolds to produce engineer cartilage for damaged cartilage repair. This book chapter has summarized recent progress in cartilage tissue engineering including stem cells, growth factors, bioactive molecules, and biomaterial scaffolds used for cartilage regeneration. The procedures for some new approaches have also been described.
- 5 June 2019
- Published by IntechOpen
Open AccessCurrent Tissue Engineering Approaches for Cartilage Regeneration
Cartilage is one of the critical tissues existed in human and animal bodies. Unlike most tissues, cartilage does not have blood vessels, nerves, and lymphatics. Most cartilage tissues in vivo are subjected to large mechanical loads, and its principal function is to provide a smooth and lubricated surface to facilitate the transmission of mechanical loads with a low frictional coefficient. As a result, cartilage tissues are easily injured. Cartilage defects are frequently caused by trauma, aging, congenital diseases (osteochondritis), and many more factors such as endocrine pathologies and cancer. The damaged cartilage has a limited capacity for healing and repairing. Thus, restoration of normal structure and function to damaged cartilage is one of the most challenging areas in orthopedic research and sports medicine. Tissue engineering provides a prospective alternative strategy by seeding chondrogenic cells into or onto biocompatible scaffolds to produce engineer cartilage for damaged cartilage repair. This book chapter has summarized recent progress in cartilage tissue engineering including stem cells, growth factors, bioactive molecules, and biomaterial scaffolds used for cartilage regeneration. The procedures for some new approaches have also been described.
- 25 May 2019
- Vol. 32 (5) , 444-447
[Clinical observation of iron sucrose combined with recombinant human erythropoietin in the treatment of anemia of hip fracture in elderly patients].
To explore the clinical efficacy of iron sucrose combined with recombinant human erythropoietin(EPO) for the treatment of anemia in elderly patients with hip fracture. From February 2016 to April 2018, 96 elderly anemia patients who underwent hip fracture surgery were divided into three groups according to the treatment methods. All the three groups received anti-anemia treatment 3 days before operation. Among them, 32 cases in group A were treated with iron sucrose alone, 32 cases in group B were treated with recombinant human erythropoietin alone, and 32 cases in group C were treated with iron sucrose combined with recombinant human erythropoietin. The therapeutic effects of the three groups were observed and compared. The clinical effective rate in group C was significantly higher than that in group A and B (P0.05), but the transfusion rate in group C was significantly lower than that in group A and B (P0.05), but the above indexes in group C were significantly higher than those in group A and B(P0.05). Compared with single drug, the combined use of sucrose and iron and recombinant human erythropoietin in the treatment of elderly hip fracture anemia has a definite effect. It can not only effectively improve the level of hemoglobin, ensure the smooth operation, but also reduce the blood transfusion rate of patients and promote their recovery after operation.
- 25 May 2019
- Vol. 32 (5) , 444-447
[Clinical observation of iron sucrose combined with recombinant human erythropoietin in the treatment of anemia of hip fracture in elderly patients].
To explore the clinical efficacy of iron sucrose combined with recombinant human erythropoietin(EPO) for the treatment of anemia in elderly patients with hip fracture. From February 2016 to April 2018, 96 elderly anemia patients who underwent hip fracture surgery were divided into three groups according to the treatment methods. All the three groups received anti-anemia treatment 3 days before operation. Among them, 32 cases in group A were treated with iron sucrose alone, 32 cases in group B were treated with recombinant human erythropoietin alone, and 32 cases in group C were treated with iron sucrose combined with recombinant human erythropoietin. The therapeutic effects of the three groups were observed and compared. The clinical effective rate in group C was significantly higher than that in group A and B (P0.05), but the transfusion rate in group C was significantly lower than that in group A and B (P0.05), but the above indexes in group C were significantly higher than those in group A and B(P0.05). Compared with single drug, the combined use of sucrose and iron and recombinant human erythropoietin in the treatment of elderly hip fracture anemia has a definite effect. It can not only effectively improve the level of hemoglobin, ensure the smooth operation, but also reduce the blood transfusion rate of patients and promote their recovery after operation.